Zobrazeno 1 - 10
of 2 091
pro vyhledávání: '"PSMA PET"'
Autor:
Matthijs Duijn, MD, Marina C. Hovius, MD, Gyorgio J. Seedo, MD, Philippe C. Baars, MD, Yves J.L. Bodar, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 19, Iss 12, Pp 6175-6178 (2024)
Primary metastatic prostate cancer to the orbit is exceedingly rare. Benign lesions, including meningioma, have demonstrated PSMA expression and can be visualized using PSMA-based PET tracers. We report the findings of 18F-PSMA-1007 PET/CT in a 76-ye
Externí odkaz:
https://doaj.org/article/f0b4a22278e647cc8f2c72db86e20b28
Publikováno v:
Radiology Case Reports, Vol 19, Iss 10, Pp 4122-4126 (2024)
A 54-year-old male with biopsy-confirmed Gleason 4+4 prostate cancer underwent 18F-DCFPyL-PSMA PET scan to identify occult metastatic disease. This scan revealed abnormal radionuclide uptake not only in the prostate but also within the patient's vasc
Externí odkaz:
https://doaj.org/article/cba81242468c42f1ac3692fa22edadff
Autor:
Dheeratama Siripongsatian, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Natphimol Boonkawin, Sukanya Yaset, Sirinsuda Somboon, Chanisa Chotipanich
Publikováno v:
Indian Journal of Radiology and Imaging, Vol 34, Iss 04, Pp 579-587 (2024)
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying
Externí odkaz:
https://doaj.org/article/cfbdec4d3c9e4966b21c1811fc8c80f4
Autor:
David Ventura, Philipp Rassek, Philipp Schindler, Burak Han Akkurt, Linus Bredensteiner, Martin Bögemann, Katrin Schlack, Robert Seifert, Michael Schäfers, Wolfgang Roll, Kambiz Rahbar
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is an essential tool for patient selection before radioligand therapy (RLT). Interim-staging with PSMA-PET during RLT allows for therapy monitoring. Howeve
Externí odkaz:
https://doaj.org/article/df3f1ee603084bb3b65b7c49acbc1e64
Publikováno v:
Current Directions in Biomedical Engineering, Vol 10, Iss 1, Pp 69-72 (2024)
We present a novel tool designed for the semiautomatic detection and assessment of prostate cancer during recurrence diagnostics using PET-CT with prostate-specific membrane antigen (PSMA). The tool automatically generates a structured report, which
Externí odkaz:
https://doaj.org/article/6d8e12b99bbc486f9b61bd9d57ccd2e2
Autor:
Sara Harsini, Patrick Martineau, Sonia Plaha, Heather Saprunoff, Catherine Chen, Julia Bishop, Scott Tyldesley, Don Wilson, François Bénard
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming standard of care for men with biochemical recurrence (BCR) of prostate cancer. The implications of a negative PSMA PET
Externí odkaz:
https://doaj.org/article/fc63f15514ae4d34906295b7b16f298f
Autor:
Benjamin Challis, Andrew Kneebone, Thomas Eade, Lesley Guo, John Atyeo, Chris Brown, George Hruby
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 50, Iss , Pp 100896- (2025)
Background: Nodal only recurrence post radical prostatectomy (RP) is increasingly recognised in the PSMA scan era. Management is controversial with a curative approach usually incorporating prostate bed and nodal irradiation (PB + NRT) in combination
Externí odkaz:
https://doaj.org/article/3ac6f05ade5d4ff4a033ff1bb3cfad40
Publikováno v:
Radiology Case Reports, Vol 19, Iss 6, Pp 2367-2370 (2024)
Prostate cancer brain metastases are rare but increasingly recognized with prostate-specific membrane antigen (PSMA) PET/CT. Distinguishing tumor response from postradiation changes are challenging on MRI. PSMA PET/CT may clarify equivocal brain lesi
Externí odkaz:
https://doaj.org/article/0888bce9624b488eacabe413ef26605f
Autor:
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to n
Externí odkaz:
https://doaj.org/article/b04bf9cbe61641e8b0c83eb5935c6d9f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.